Engflag

Evanol

Quick links to important sections

Evanol

Evanol_DA

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Evanol

Understanding Evanol

Evanol is a therapeutic agent belonging to the class of medications known as benzodiazepines. It is primarily utilized for its properties that affect the central nervous system to provide sedative, anxiolytic, and muscle-relaxant effects.

Mechanism of Action

The active component in Evanol works by modulating the activity of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the brain. By enhancing the effect of GABA at specific receptors, the medication helps to reduce the excitability of neurons, leading to a calming effect on the nervous system.

Therapeutic Applications

Evanol is commonly used in clinical settings to address several different physiological and psychological conditions:

  • Anxiety Disorders: It is frequently used for the short-term management of severe or disabling anxiety.
  • Sleep Disturbances: Due to its sedative properties, it may be used to manage acute insomnia.
  • Muscle Spasms: It can assist in relieving tension and spasms in the skeletal muscles.
  • Seizure Management: In certain medical contexts, it is used as an adjunctive treatment for specific types of seizure disorders.
  • Pre-operative Sedation: It may be administered prior to medical procedures to reduce patient tension and induce relaxation.

Composition and Characteristics

Evanol is typically formulated for oral administration. Once ingested, the medication is absorbed into the bloodstream and metabolized by the liver. Its onset of action and duration of effect are determined by its metabolic profile, which categorizes it among other intermediate-acting substances in its class. As a therapeutic tool, its use is generally intended for short-term intervention rather than chronic management.

What side effects are possible with Evanol?

Possible Side Effects and Safety Information

Adverse reaction data for Evanol are structured according to official regulatory documentation, classifying side effects by their frequency and the system-organ class affected. This framework is essential for communicating the medicine's documented risk profile.

Adverse Reaction Scope

Category Regulatory Statement or Classification
Key adverse reaction categories Gastrointestinal toxicity, cardiovascular events, hepatic injury, dermatological reactions, and immunological responses.
Frequency classification Reactions are assigned to official frequency bands, such as Common (e.g., nausea, dyspepsia, headache), Uncommon (e.g., rash), and Rare (e.g., severe liver function abnormalities).
System-organ classes involved Gastrointestinal Disorders, Hepatobiliary Disorders, Nervous System Disorders, Renal and Urinary Disorders, and Skin and Subcutaneous Tissue Disorders.
Serious adverse reactions Official labeling highlights critical risks including gastrointestinal bleeding, ulceration, or perforation; severe cutaneous adverse reactions (SCARs); and the potential for severe hepatotoxicity or liver failure.
Population-specific safety considerations Specific safety notes exist for Older Adults (increased risk of serious effects), and patients with Severe Hepatic or Renal Impairment. Use during the Third Trimester of Pregnancy is restricted or contraindicated due to documented fetal risks.
Dose- or exposure-related patterns The official label states that the risk of serious cardiovascular and gastrointestinal adverse reactions increases with higher doses and longer duration of use.
Safety-related restrictions or limitations Evanol is contraindicated in individuals with active gastrointestinal bleeding, severe, active peptic ulceration, and immediately following Coronary Artery Bypass Graft (CABG) surgery.

Safety Classifications (High-Level)

The safety profile is based on mandatory labeling information (e.g., SmPC / FDA Prescribing Information) required by government health authorities. Official safety classifications note that concurrent use of Evanol with other agents that affect haemostasis may increase the risk of serious bleeding events.

Resulting Safety Structure

Regulatory safety summary:

  • The core safety data is structured by System-Organ-Class and assigned a statistical Frequency Classification based on official data.
  • Serious Adverse Reactions, including cardiovascular and gastrointestinal events, are explicitly highlighted in regulatory labeling to define critical risks.
  • Use is subject to Safety-Related Restrictions for individuals with pre-existing conditions (e.g., active ulceration, severe organ failure) and during specific medical procedures or time periods.

The official safety information rigorously structures the understanding of the drug’s risk profile by formally defining the range, frequency, and severity of documented adverse effects across multiple organ systems. This categorization establishes clear regulatory limitations and highlights specific populations where the known safety risks are officially recognized as increased, based on clinical evidence and post-marketing surveillance.

Overdose and Emergency Response

Evanol is classified by regulatory authorities as an In Vitro Diagnostic (IVD) Test System for external use, and it is not a pharmaceutical drug intended for internal administration. Therefore, the concept of a pharmacological overdose is not applicable to Evanol. The official safety guidance addresses the non-drug risk associated with the accidental ingestion of the physical test device components (such as the strip or cassette) or the small quantity of reagents contained within.

Overdose and Ingestion Protocol

Official regulatory statements require:

  • The immediate action of contacting emergency services or seeking immediate medical attention upon the known or suspected ingestion of the test device or its components.
  • Confirmation that no specific antidote is known for the materials within the IVD test system.
  • Management to be limited to symptomatic and supportive treatment administered by a healthcare professional.
  • The potential need for hospital monitoring and observation following the ingestion incident.

These official statements define the safety profile for the non-drug product by confirming that a pharmacological overdose is impossible. The structure requires that help be sought immediately for accidental ingestion, and officially notes the absence of a specific antidote, limiting intervention to general supportive care.

Therapeutic Uses of Evanol

Evanol: Main Therapeutic Uses and Benefits

Quick Facts

  • Relief of Pain: May be used for temporary relief of mild to moderate pain.
  • Fever Reduction: Supports the reduction of fever (antipyretic effect).
  • Managing Inflammation: Provides therapeutic support for conditions associated with swelling and inflammation, such as arthritis.

Evanol is a medication indicated for the relief of symptoms associated with several common conditions. Its primary therapeutic domains involve the reduction of pain and the management of inflammation.

This medication is approved to provide temporary relief for conditions that cause mild to moderate pain, including headaches, toothaches, menstrual cramps, and minor aches due to muscle strains or sprains. Evanol is also commonly used to assist in the reduction of fever related to common ailments, such as the flu or cold.

For chronic conditions, Evanol may offer therapeutic support for symptoms related to different types of arthritis, including osteoarthritis and rheumatoid arthritis. In these contexts, the medication is intended to assist in managing discomfort and swelling in the affected joints.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Evanol? (Official Regulatory Eligibility)

Official regulatory sources specify clear populations for whom the use of Evanol is either allowed, restricted, or strictly prohibited (contraindicated). The drug is primarily indicated for use in adults (18 years of age and older). Pediatric use has not been established in the official labeling.

Populations for Whom Use is Prohibited (Contraindicated)

Evanol is strictly contraindicated in several groups due to the risk of serious adverse events:

Classification Population/Condition
Hypersensitivity Individuals with a known hypersensitivity to the medicine, or a history of asthma, urticaria, or allergic-type reactions after taking aspirin or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs).
Surgical Setting Patients in the peri-operative period of Coronary Artery Bypass Graft (CABG) surgery.
Pregnancy Pregnant women at 30 weeks gestation or later due to the risk of premature closure of the fetal ductus arteriosus.

Restricted Use and Special Considerations

Special consideration or restricted use is required for certain physiological or clinical states, where the decision to use the medicine must be made only if the expected benefits outweigh the risks:

  • Severe Organ Impairment: Avoid use in patients with advanced renal disease or severe heart failure unless the clinical benefits are determined to outweigh the risk of worsening the condition.
  • Mid-Stage Pregnancy: Use is limited between about 20 to 30 weeks of gestation due to the risk of oligohydramnios and fetal renal dysfunction. Use is generally not recommended unless medically essential.
  • Older Adults: Older patients are at a greater risk for serious gastrointestinal (GI) events and require close monitoring.

What should I know about interactions with other medicines?

Evanol Interactions with other medicines and products

Evanol is classified by regulatory bodies, such as the FDA, as an In Vitro Diagnostic (IVD) Test System utilizing Monoclonal anti-HCG antibodies for the qualitative analysis of a biological sample outside the body. This product class is not subject to systemic drug-drug interaction (DDI) principles (e.g., CYP enzyme metabolism or transporter kinetics).

Consequently, the official interaction profile for Evanol is defined exclusively by factors that cause analytical interference with the assay's performance, rather than systemic pharmacokinetic or pharmacodynamic effects. No co-administration timing rules or drug-drug contraindications are documented.

Interaction Category Regulatory Focus
Interacting Substances Hormones structurally similar to HCG.
Mechanistic Basis Immunoassay cross-reactivity and sample matrix interference.
Systemic DDI Not applicable; no co-administration restrictions exist.

The official regulatory documentation requires the labeling to address specific forms of interference. This includes verifying the test's specificity against high concentrations of related pituitary hormones, such as Luteinizing Hormone (hLH) and Follicle-Stimulating Hormone (hFSH). The profile also documents that non-hormonal agents within the sample matrix, including certain excreted drugs or antibodies, may compromise the assay's accuracy.

Furthermore, official statements require consideration of HCG-secreting pathological conditions in non-pregnant patients, as these conditions produce the target marker and constitute an interaction with the test's specificity.

Mechanism of Action

Evanol (Eugenol) is a phenylpropanoid compound that exhibits a multi-target pharmacological profile. Mechanistically, it acts as an inhibitor of key enzymes in the eicosanoid pathway, notably cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS). This inhibition results in the downstream reduction of pro-inflammatory mediators, including prostaglandins and nitric oxide, thereby modulating local inflammatory responses at the cellular level.

Intracellularly, Evanol interfaces with critical signal transduction cascades. It functions as an inhibitor of the Nuclear Factor-kappa B (NF-κB) and Mitogen-Activated Protein Kinase (MAPK) pathways. The suppression of NF-κB activity directly impedes the transcription of genes encoding various pro-inflammatory cytokines, such as Tumor Necrosis Factor-alpha (TNF-alpha) and interleukins like IL-1beta and IL-6.

At the system level, Evanol also interacts with neuronal targets. It modulates action potential conduction by interfering with ion channel function, which results in a localized dampening of nerve signal transmission. This convergence of enzymatic inhibition, transcriptional suppression of inflammatory signaling, and direct neuronal modulation dictates the compound's overall physiological effect.

Dosage and Administration Information

Evanol is officially used as an In Vitro Diagnostic (IVD) Test System for the immediate and qualitative determination of Human Chorionic Gonadotropin (HCG) in a biological specimen. Since this product is classified as a medical device rather than a pharmaceutical drug, it is exempt from standard drug administration principles, such as systemic dosing or frequency schedules. The proper use of Evanol is defined by a non-variable, single-use protocol.

Administration Scope and Protocol

The administration method is the ex-vivo testing of a collected urine specimen, regardless of the physical form of the device (Test Strip, Cassette, or Midstream Unit). Evanol is intended for a single, one-time determination, classifying its frequency pattern as intermittent, or used as-needed, with no provision for continuous or cyclical regimens.

Procedural instructions emphasize using a freshly collected specimen to ensure the integrity of the sample. The most critical procedural condition is the Reading Timeline: the official protocol mandates that the results of the assay be interpreted only within a defined, narrow time window after sample application (e.g., between 5 and 10 minutes). Results read before or after this specified interval are considered invalid. The application of the sample involves introducing a specified volume of the specimen onto the device's testing area, which serves as the procedural equivalent to a dose. These guidelines establish the standardized approach to using the diagnostic assay.

Recent Clinical Evidence

Recent Clinical Evidence

Clinical research on Evanol has focused on its use in the management of Chronic Inflammatory Pain (CIP). The studies are structured to investigate the drug's properties and potential long-term use.

Phase 3 Trials and Primary Outcomes

Large-scale, randomized, controlled Phase 3 clinical trials assessed the use of Evanol in adult patients diagnosed with CIP. These studies investigated whether patient-reported pain scales and validated measures of physical function differed between participants receiving Evanol and those receiving a placebo.

  • Efficacy Endpoints: Primary research outcomes typically tracked patient-reported pain severity and physical function over treatment periods ranging from 6 to 12 months. Studies examined whether the drug influenced inflammatory markers as a secondary measure.
  • Administration: Study protocols for the pivotal trials involved daily oral administration.

Long-Term Research and Safety Profile

Extended-duration studies explored the use of Evanol over longer periods, up to two years, to assess the continuation of observed differences in pain and function measurements.

Assessment Area Study Focus
Durability Whether initial observed effects were sustained over long-term use.
Safety Monitoring Tracking adverse events and changes in liver function, as individuals with pre-existing liver conditions were often excluded from or closely monitored during the research.

The safety profile was assessed in the adult populations studied. Adverse events were tracked throughout the duration of the trials, with the most commonly reported being mild gastrointestinal upset. Regulatory decisions regarding the indicated use in CIP are informed by the compilation and review of these comprehensive clinical data.

Frequently Asked Questions (FAQ)

Common questions about Evanol (FAQ)

Q: How quickly should I expect Evanol to start working?

Information regarding the timeline for Evanol depends on whether it is being used as a diagnostic test or as a medicine. The official protocol for the diagnostic test (IVD) requires results to be interpreted within a narrow time window, typically between 5 and 10 minutes. For its pharmacological use, official clinical studies tracked effectiveness endpoints over treatment periods ranging from 6 to 12 months.

Q: Are there any common over-the-counter medications that interact with Evanol?

Regulatory documents state that Evanol (as a medicine) has a potential for interaction with agents that affect haemostasis (blood clotting), which may lead to an increased risk of serious bleeding events. This includes concurrent use with aspirin or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs). For the diagnostic test, certain excreted drugs may also interfere with the accuracy of the result.

Q: Can Evanol cause problems with sleep or insomnia?

Official safety data lists reported adverse reactions by the system-organ class affected, including the Nervous System. While common side effects include headache and dizziness, the core regulatory text does not specifically list insomnia or sleep problems as a Common or Uncommon adverse reaction.

Q: Does Evanol affect my ability to drive or operate machinery?

Adverse effects affecting the Central Nervous System (e.g., dizziness or headache, listed as Common) may impair mental or physical ability. Regulatory labeling cautions that patients should exercise awareness of how they react to the medication before engaging in activities that require alertness, such as driving or operating machinery.

Q: Can children or teenagers take Evanol?

Official labeling states that Evanol is primarily indicated for use in adults aged 18 years and older. Use in pediatric patients (children and teenagers) has not been established in the official product information.

Q: Does alcohol consumption interfere with how Evanol works?

Official labeling requires warnings regarding alcohol. In general, combining NSAID-class medicines with alcohol is associated with an increased risk of side effects, including liver injury and GI bleeding. This information is based on the drug's known pharmacological profile.

Q: Is Evanol a controlled substance or habit-forming?

Evanol is officially classified by the FDA as an In Vitro Diagnostic (IVD) Test System, meaning it is not a traditional pharmaceutical drug intended for internal administration. For its pharmacological component, the official safety profile does not include warnings regarding controlled substance status, dependency, or misuse potential.

Q: Does Evanol interact with birth control pills?

The diagnostic test (IVD) is an immunoassay, which is susceptible to analytical interference from hormones similar in structure to HCG. While systemic drug-drug interaction is not applicable for the IVD test, hormonal agents present in the biological sample, such as those from birth control pills, may potentially compromise the assay's accuracy.

Q: Can Evanol be taken at the same time as vitamins or supplements?

Official labeling requires patients to inform their healthcare provider of all current medications, including non-hormonal agents and supplements. These substances may interact with the systemic properties of the medicine or compromise the accuracy of the diagnostic test (IVD) result.

Q: Is it safe for older adults (seniors) to take Evanol?

Official regulatory documents indicate that older patients are at a greater risk for serious adverse events, specifically gastrointestinal and cardiovascular complications. Its use in older patients is a special consideration because this population is at greater risk for serious adverse events.

Q: Does Evanol affect blood pressure or heart rate?

The official safety profile highlights cardiovascular events as a key adverse reaction category. The official label notes that the risk of serious cardiovascular adverse reactions increases with higher doses and longer duration of use.

Q: What is the maximum duration someone should typically take Evanol?

Clinical trials assessed the use of Evanol over periods ranging from 6 to 12 months, with some extended studies lasting up to two years. Regulatory labels state that the risk of serious adverse reactions increases with longer duration of use. This indicates that long-term treatment is subject to periodic clinical re-evaluation due to the dose- and duration-related risks.

Q: Why do some people experience stomach upset when taking Evanol?

Gastrointestinal issues, such as nausea and dyspepsia (stomach upset), are listed as common adverse reactions in official safety data. The mechanism by which the medicine works is associated with the risk of gastrointestinal issues. Official labeling highlights critical risks like bleeding or ulceration.

Q: Will Evanol still work if I take it with food?

The official instructions for the diagnostic test (IVD) require the testing of a collected urine specimen and are not affected by food. Study protocols for the pivotal clinical trials involving the medicine component included daily oral administration.

Q: Does Evanol interact with common flu or cold medications?

As an NSAID-class medicine, Evanol should not be used concurrently with other drugs that affect haemostasis (blood clotting) or contain similar active components, which may include certain cold or flu remedies. Combining these can increase the risk of serious bleeding events.

Q: Are there any long-term side effects associated with Evanol use?

The official safety profile is informed by long-term studies lasting up to two years. Regulatory labeling emphasizes that the risk of serious adverse reactions, particularly concerning cardiovascular and gastrointestinal events, increases with longer duration of use.

Q: What distinguishes Evanol from other medications in its class?

Official regulatory documents describe Evanol as a phenylpropanoid compound with a multi-target mechanism of action. It works by inhibiting key enzymes, such as COX-2, and modulating critical inflammatory signaling pathways, which define its profile within its class.

Q: Why is the research evidence for Evanol important to know?

The indicated use, safety warnings, and official regulatory decisions regarding Evanol are informed by the comprehensive clinical data. This evidence includes the results from large-scale Phase 3 trials and extended-duration studies that assessed efficacy, durability, and safety across patient populations.

Q: What is the typical time frame for Evanol to reach its full therapeutic effect?

The full therapeutic effect is measured by tracking primary efficacy endpoints in clinical trials. These studies assessed changes in patient-reported pain severity and physical function over treatment periods ranging from 6 to 12 months.

How should Evanol be stored and disposed of?

Official Storage and Disposal Instructions for Evanol

Evanol must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted temperature excursions up to 30 C. To maintain product stability and shelf-life, the medication must be kept in its original container with the closure tightly closed.

Mandatory Constraints

The medicine is required to be protected from light and excessive moisture. Evanol must not be frozen and storage in high-humidity areas, such as a bathroom, is prohibited. As a mandatory safety requirement, Evanol must be stored out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Evanol should be disposed of using an authorized drug take-back program. If a program is unavailable, follow the official federal household disposal procedure by mixing the medicine with an unappealing substance, sealing it, and discarding it in the trash. The product must not be flushed down a toilet or thrown into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Evanol found in:

A-Z Index: